• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

专题:“肝纤维化发病机制的细胞和分子机制”

Special Issue on "Cellular and Molecular Mechanisms Underlying the Pathogenesis of Hepatic Fibrosis".

机构信息

Institute of Molecular Pathobiochemistry, Experimental Gene Therapy and Clinical Chemistry (IFMPEGKC), RWTH University Hospital Aachen, D-52074 Aachen, Germany.

出版信息

Cells. 2020 Apr 29;9(5):1105. doi: 10.3390/cells9051105.

DOI:10.3390/cells9051105
PMID:32365575
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7291324/
Abstract

This Special issue contains 48 contributions highlighting novel findings and current concepts in basic and clinical liver fibrosis research. These articles emphasize issues on pathogenesis, cellular mediators, modulators, molecular pathways, disease-specific therapies, scoring systems, as well as novel preclinical animal models for the study of liver fibrogenesis. This editorial aims to briefly summarize the content of these papers.

摘要

本期特刊包含 48 篇文章,重点介绍了基础和临床肝纤维化研究中的新发现和当前概念。这些文章强调了发病机制、细胞介质、调节剂、分子途径、针对特定疾病的治疗方法、评分系统以及用于研究肝纤维化的新型临床前动物模型等问题。本社论旨在简要总结这些论文的内容。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5f6b/7291324/bac4741f6288/cells-09-01105-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5f6b/7291324/bac4741f6288/cells-09-01105-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5f6b/7291324/bac4741f6288/cells-09-01105-g001.jpg

相似文献

1
Special Issue on "Cellular and Molecular Mechanisms Underlying the Pathogenesis of Hepatic Fibrosis".专题:“肝纤维化发病机制的细胞和分子机制”
Cells. 2020 Apr 29;9(5):1105. doi: 10.3390/cells9051105.
2
Current and future anti-fibrotic therapies for chronic liver disease.慢性肝病的当前及未来抗纤维化疗法
Clin Liver Dis. 2008 Nov;12(4):939-62, xi. doi: 10.1016/j.cld.2008.07.011.
3
Optimized Mouse Models for Liver Fibrosis.肝纤维化的优化小鼠模型
Methods Mol Biol. 2017;1559:279-296. doi: 10.1007/978-1-4939-6786-5_19.
4
Cellular mechanisms of tissue fibrosis. 5. Novel insights into liver fibrosis.细胞组织纤维化的机制。5. 肝脏纤维化的新见解。
Am J Physiol Cell Physiol. 2013 Oct 15;305(8):C789-99. doi: 10.1152/ajpcell.00230.2013. Epub 2013 Jul 31.
5
Special Issue on "Cellular and Molecular Mechanisms Underlying the Pathogenesis of Hepatic Fibrosis II".专题:“肝纤维化发病机制的细胞和分子机制 II”
Cells. 2022 Aug 4;11(15):2403. doi: 10.3390/cells11152403.
6
[Current findings in hepatic fibrogenesis].[肝纤维化形成的当前研究结果]
Rev Med Interna Neurol Psihiatr Neurochir Dermatovenerol Med Interna. 1990 Mar-Apr;42(2):111-8.
7
Liver fibrogenesis and the role of hepatic stellate cells: new insights and prospects for therapy.肝纤维化形成及肝星状细胞的作用:新见解与治疗前景
J Gastroenterol Hepatol. 1999 Jul;14(7):618-33. doi: 10.1046/j.1440-1746.1999.01928.x.
8
Pathogenesis of hepatic fibrosis and the role of cytokines.肝纤维化的发病机制及细胞因子的作用。
J Clin Gastroenterol. 1992 Jul;15(1):63-7. doi: 10.1097/00004836-199207000-00015.
9
The role of the sphingolipid pathway in liver fibrosis: an emerging new potential target for novel therapies.鞘脂代谢通路在肝纤维化中的作用:新型治疗药物的新兴潜在靶点。
Am J Physiol Cell Physiol. 2020 Jun 1;318(6):C1055-C1064. doi: 10.1152/ajpcell.00003.2020. Epub 2020 Mar 4.
10
Connective tissue biology and hepatic fibrosis: report of a conference.结缔组织生物学与肝纤维化:会议报告
Hepatology. 1990 Mar;11(3):488-98. doi: 10.1002/hep.1840110322.

引用本文的文献

1
System Biology Investigation Revealed Lipopolysaccharide and Alcohol-Induced Hepatocellular Carcinoma Resembled Hepatitis B Virus Immunobiology and Pathogenesis.系统生物学研究揭示脂多糖和酒精诱导的肝细胞癌类似于乙型肝炎病毒的免疫生物学和发病机制。
Int J Mol Sci. 2023 Jul 6;24(13):11146. doi: 10.3390/ijms241311146.

本文引用的文献

1
The P2X7 Receptor and NLRP3 Axis in Non-Alcoholic Fatty Liver Disease: A Brief Review.P2X7 受体和 NLRP3 轴在非酒精性脂肪性肝病中的作用:简要综述。
Cells. 2020 Apr 22;9(4):1047. doi: 10.3390/cells9041047.
2
Liver Fibrosis: Mechanistic Concepts and Therapeutic Perspectives.肝纤维化:机制概念与治疗视角。
Cells. 2020 Apr 3;9(4):875. doi: 10.3390/cells9040875.
3
Relationship between Heart Disease and Liver Disease: A Two-Way Street.心脏病与肝病的关系:双向影响。
Cells. 2020 Feb 28;9(3):567. doi: 10.3390/cells9030567.
4
Antifibrotic Effects of Amyloid-Beta and Its Loss in Cirrhotic Liver.淀粉样蛋白-β的抗纤维化作用及其在肝硬化中的缺失。
Cells. 2020 Feb 17;9(2):452. doi: 10.3390/cells9020452.
5
Cellular Interplay as a Consequence of Inflammatory Signals Leading to Liver Fibrosis Development.细胞相互作用是炎症信号导致肝纤维化发展的结果。
Cells. 2020 Feb 18;9(2):461. doi: 10.3390/cells9020461.
6
α2-Adrenergic Receptor in Liver Fibrosis: Implications for the Adrenoblocker Mesedin.α2-肾上腺素能受体在肝纤维化中的作用:对肾上腺素能阻滞剂美司亭的影响。
Cells. 2020 Feb 18;9(2):456. doi: 10.3390/cells9020456.
7
Dynamic Changes in Function and Proteomic Composition of Extracellular Vesicles from Hepatic Stellate Cells during Cellular Activation.细胞激活过程中肝星状细胞外囊泡功能和蛋白质组组成的动态变化。
Cells. 2020 Jan 25;9(2):290. doi: 10.3390/cells9020290.
8
Glycochenodeoxycholate Promotes Liver Fibrosis in Mice with Hepatocellular Cholestasis.甘氨鹅脱氧胆酸促进肝内胆汁淤积小鼠肝纤维化。
Cells. 2020 Jan 23;9(2):281. doi: 10.3390/cells9020281.
9
Four-And-A-Half LIM-Domain Protein 2 (FHL2) Deficiency Aggravates Cholestatic Liver Injury.四半 LIM 结构域蛋白 2(FHL2)缺乏加重胆汁淤积性肝损伤。
Cells. 2020 Jan 19;9(1):248. doi: 10.3390/cells9010248.
10
Transcriptional Suppression of the NLRP3 Inflammasome and Cytokine Release in Primary Macrophages by Low-Dose Anthracyclines.低剂量蒽环类药物对原代巨噬细胞中 NLRP3 炎性体和细胞因子释放的转录抑制作用。
Cells. 2019 Dec 28;9(1):79. doi: 10.3390/cells9010079.